Objective: We evaluated the feasibility of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high-risk or recurrent endometrial cancer. Methods: Women with histologically confirmed FIGO Stages I -II with .1/2 myometrial invasion, Stage III/IV or recurrent endometrial cancer were enrolled. Patients received intravenous doxorubicin (45 mg/m 2 ), followed by cisplatin (50 mg/m 2 ) on Day 1 and intravenous paclitaxel (160 mg/m 2 ) on Day 2. Granisetron (75 mg) was administered depending on neutrophil counts on Days 3 and 8. Treatment was repeated every 21 days for six cycles or until disease progression or unacceptable toxicity. The primary endpoint was the completion rate of the scheduled chemotherapy; secondary endpoints were Grade 3/4 toxicity and response rate in patients with measurable lesions. Results: From September 2010 to December 2012, 35 women, including 7 with FIGO Stage I, 4 with Stage II, 13 with Stage III, 10 with Stage IV and 1 with recurrent endometrial cancer, were enrolled. There were 26 endometrial carcinomas (Grade 1, 16; Grade 2, 6; Grade 3, 4), 4 carcinosarcomas, 2 serous adenocarcinomas, 1 neuroendocrine carcinoma, 1 poorly differentiated carcinoma and 1 mixed carcinoma. Twenty-five patients (71%) completed six chemotherapy cycles. Grade 3/4 hematological toxicities included neutrocytopenia (97%), thrombocytopenia (6%) and anemia (34%). Three patients (9%) experienced neutropenic fever. Grade 3/4 non-hematological toxicities were observed in 13 patients. In 15 patients with evaluable lesions, the response rate was 80%. Conclusions: Combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection is feasible.
INTRODUCTION
Adjuvant chemotherapy after surgical debulking is now the mainstay of treatment for women with advanced endometrial cancer. Drugs used for treating endometrial cancer include platinum agents, taxanes and anthracyclines, all of which have response rates .20% (1) . Of the various combination regimens evaluated in randomized studies, the most powerful regimen till date is a three-drug regimen (TAP therapy) consisting of cisplatin (50 mg/m 2 ), doxorubicin (45 mg/m 2 ) and paclitaxel (160 mg/m 2 ) (2). This regimen was compared with a combination of cisplatin (50 mg/m 2 ) and doxorubicin (60 mg/m 2 ) in the Gynecologic Oncology Group (GOG) 177 study. The objective response rate increased from 34 (cisplatin/doxorubicin) to 57% (TAP), and the overall survival improved from 12.3 months (cisplatin/doxorubicin) to 15.3 months (TAP). TAP therapy required the administration of prophylactic granulocyte colony-stimulating factor (G-CSF) support because a high frequency of severe neutropenia was observed in a dose-determination study (3) . Grade 3 and 4 thrombocytopenia was high (21%) in patients undergoing TAP therapy; however, other hematological toxicities were ameliorated with G-CSF.
Since 1961, Japan has had a universal public pension insurance system extending to all citizens. This system does not cover preventive healthcare. Therefore, most Japanese healthcare facilities have not been able to provide prophylactic medical care such as prophylactic G-CSF support in daily medical practice. Furthermore, TAP has not been universally accepted as a standard therapy owing to concerns among Japanese gynecologic oncologists regarding hematological and non-hematological toxicities.
The present study aimed to evaluate the feasibility of TAP therapy without prophylactic G-CSF support (modified TAP therapy) in Japanese women. The results of the present study will provide useful information regarding the use of TAP therapy in Japan.
PATIENTS AND METHODS

PATIENTS
Women who met the following criteria were enrolled in the present study: (i) histologically proven endometrial cancer, including carcinosarcoma; (ii) FIGO Stage I/II with myometrial invasion .1/2, FIGO Stage III/IV or recurrent endometrial cancer; (iii) an Eastern Cooperative Oncology Group performance status (PS) of 0 -2; (iv) life expectancy .3 months; (v) age of 20 years or older; (vi) adequate bone marrow and organ function (neutrophils .1500/mm 3 , platelets .100 000/mm 3 , serum transaminase levels not .2 times the upper limit of normal, total bilirubin ,1.5 mg/dl, serum creatinine ,1.5 mg/dl); (vii) normal electrocardiogram and (viii) a left ventricular ejection fraction (LVEF) 50%. Women who had sarcoma, pleural effusion or ascites that required drainage, brain metastasis, previous administration of anthracyclines or active concomitant malignancy were excluded. Patients with serious concomitant medical illness, including uncontrolled infection or angina, serious neuropathy or active concomitant malignancy, were also ineligible.
TREATMENT
Women had to be enrolled within 6 weeks of surgery. The protocol therapy consisted of doxorubicin at 45 mg/m 2 (in 50 ml saline, infused over 30 min), followed by cisplatin at 50 mg/m 2 (in 500 ml saline, infused over 2 h) on Day 1 and paclitaxel at 160 mg/m 2 (in 500 ml saline, infused over 3 h) on Day 2. Chemotherapy was scheduled to repeat every 21 days for six cycles or until disease progression or unacceptable toxicity. All the patients were administered antiemetic and antiallergic therapy with palonosetron, antihistamine, dexamethasone and aprepitant. Granisetron (75 mg) was subcutaneously administered daily for 10 days in patients experiencing neutrophil counts ,500/mm 3 on Day 3 or 8. Treatment was delayed when the granulocyte count was ,1500/mm 3 , platelet count was ,100 000/mm 3 or any nonhematological toxicities (excluding alopecia, malaise, nausea or constipation of Grade 2 or higher) occurred until the severity of symptoms was not higher than Grade 1. In women with febrile neutropenia, Grade 4 thrombocytopenia, or a 15-21-day treatment delay for prolonged toxicity (excluding peripheral neuropathy), the doses of doxorubicin and cisplatin were reduced in the next cycle to 30 mg/m 2 and 30 mg/m 2 , respectively. In patients who experienced Grade 3 or 4 peripheral neuropathy or a 15 -21-day treatment delay for prolonged peripheral neutropenia, paclitaxel was reduced to 125 mg/m 2 in the next cycle. The protocol therapy was discontinued in patients experiencing the following: (i) a treatment delay over 21 days for any toxicity, (ii) estimated creatinine clearance using the Cockroft -Gault formula of ,50 ml/min, (iii) a drop in LVEF ,50 or .20% decrease from the baseline value, (iv) Grade 3 or more hearing loss, (v) cumulative dose of doxorubicin ,600 mg/body, (vi) disease progression and (vii) patient refusal (4).
EVALUATION OF CHEMOTHERAPY
The primary endpoint was the rate of completion of the scheduled chemotherapy. The criterion for determining feasibility was set at 60% on the basis of a previous study (5) . Secondary endpoints were Grade 3 or 4 toxicity and the response rate.
Chemotherapy-induced toxicity was graded according to the NCI common toxicity criteria version 4.0. Tumors were measured using enhanced computed tomography scans before treatment and after every two treatment cycles in patients with measurable tumors or every three treatment cycles in patients without measurable tumors. The response was evaluated on the basis of RECIST 1.1 criteria.
The present study was approved by the institutional review board of Saitama Medical University International Medical Center. All the patients provided written informed consent prior to receiving any protocol therapy.
RESULTS
PATIENT CHARACTERISTICS
Between September 2010 and December 2012, 35 consecutive patients were enrolled in the present study. Patient characteristics are summarized in Table 1 . The median age was 60 years (range, 48 -72 years). Thirty-one patients (89%) were PS 0 and four patients were PS 1. Approximately two-third of the patients had advanced (FIGO Stage III or IV) disease. Only one patient with recurrent disease was included in the present study. Histological classifications included 26 endometrioid adenocarcinomas (Grade 1, 16; Grade 2, 6; Grade 3, 4), 2 serous adenocarcinomas, 4 carcinosarcomas and 3 other types (1 undifferentiated carcinoma, 1 small-cell carcinoma and 1 mixed-cell adenocarcinoma). Twelve patients received protocol therapy as neoadjuvant chemotherapy (NAC), 22 as adjuvant chemotherapy and 1 as salvage chemotherapy. No patient had received previous radiation therapy (RT). Fifteen patients had measurable tumors.
FEASIBILITY
Twenty-five patients (71%) completed six or more chemotherapy cycles (Table 2) . Two patients received only one chemotherapy cycle and three patients received two cycles. Reasons for interruption included patient refusal (n ¼ 3), disappointing tumor shrinkage (n ¼ 3), syndrome of inappropriate secretion of antidiuretic hormone (SIADH) caused by cisplatin (n ¼ 1), Grade 4 hyponatremia by undetermined cause (n ¼ 1), prolonged neutropenia (n ¼ 1) and Grade 3 perforation of the sigmoid colon (n ¼ 1). No patient was removed from the study because of symptomatic congestive heart failure or asymptomatic decline in LVEF. Nine patients (26%) required scheduled dose reduction owing to febrile neutropenia (n ¼ 3), prolonged neutropenia (n ¼ 5) or ileus (n ¼ 1). Table 3 shows the hematological toxicities associated with treatment. Grade 3/4 neutropenia, anemia and thrombocytopenia were observed in 97, 34 and 6%, respectively. Although only three patients (9%) experienced febrile neutropenia, the predominant toxicity was neutropenia. Granisetron was administered by injection to 22 patients (63%) at 34 cycles (18%). Three patients (9%) received a red blood cell transfusion, and one patient received a platelet transfusion. Table 4 shows the non-hematological toxicities associated with treatment. No treatment-related death was observed. One patient experienced ileus after the first chemotherapy cycle. She recovered from ileus through conservative management, Yes 0 1042 TAP therapy without prophylactic G-CSF and the protocol therapy was continued. One patient experienced perforation of the transverse colon after the second cycle and required emergency laparotomy. Postoperatively, she experienced septic shock and DIC and received intensive care. The cause was assumed to be rapid shrinkage of the tumor invading the transverse colon. Grade 2/3 muscle pain (26%), arthralgia (37%) and sensory neuropathy (31%) were frequent but did not require discontinuation of treatment. Two patients experienced severe hyponatremia and received protocol therapy as NAC because they had significantly advanced disease. The first patient experienced Grade 4 hyponatremia on Day 14 of Cycle 1. Further investigation to determine the cause of hyponatremia was not performed. The second patient encountered Grade 3 hyponatremia with general fatigue on Day 8 of Cycle 1. The cause of hyponatremia was determined to be SIADH on the basis of the value of plasma and urine osmolality (6) . These two patients recovered immediately without permanent damage.
TOXICITIES
RESPONSE
The clinical responses of 12 (80%) of the 15 patients with measurable tumors were recorded (four complete and eight partial response). Progressive disease was not observed in any patients.
DISCUSSION
The feasibility of modified TAP therapy in Japanese women was confirmed in the present study because 25 of 35 patients (71%) completed the six scheduled cycles of protocol therapy. This completion rate met the criterion for feasibility. The completion rate of modified TAP therapy was comparable with that of TC therapy in the GOG 209 study (68.8%) and exceeded that of TAP therapy in the GOG 177 (52%) and GOG 209 (62.5%) studies (2,5). Although we skipped prophylactic G-CSF support, the interruption of protocol therapy presumably resulted from hematological toxicity was observed in only one patient. The need for G-CSF support as indicated by blood cell counts on Day 3 or 8 was observed in only 34 of 186 cycles (18%). Despite the rarity of G-CSF use, febrile neutropenia occurred in three patients (9%). This rate was not much lesser than that observed using TAP therapy with prophylactic G-CSF in either the GOG 209 study (7%) or the GOG 177 study (3%) (2, 5) . In addition, only 6% of patients experienced a platelet count decrease greater than Grade 2 in the present study, which was fairly rare in comparison with the other GOG studies (22 and 23%, respectively) (2,5). Previous pelvic RT may have an impact on the patient's ability to tolerate myelosuppressive chemotherapy (3, 7, 8) . At least 50% of the patients included in many previous GOG studies for advanced endometrial cancer, including the GOG 209 and 177 studies, had received previous pelvic RT. In contrast, no patient in the present study had received previous RT (2, 9, 10) . According to the guidelines for appropriate G-CSF use by the American Society of Clinical Oncology and European Organization for Research and Treatment of Cancer, the threshold febrile neutropenia risk for recommending prophylactic use of G-CSF is 20% and above (11, 12) . Patients with no previous pelvic RT are presumed to require no G-CSF support.
All the patients in the present study received dexamethasone, palonosetron and aprepitant to prevent acute and delayed emesis. Only three patients (9%) experienced vomiting of Grade 2 or higher. In contrast, 35 of the 131 (27%) patients who received TAP therapy in the GOG 177 study experienced vomiting of Grade 2 or higher (2). The low incidence of severe emesis in the present study must be largely due to the administration of antiemetic drugs such as aprepitant (13) . On the other hand, the frequency of peripheral sensory neurotoxicity in the present study (31% Grade 2 or 3) was as high as that during TAP therapy in the GOG 209 study (30% Grade 2 or 3). Similarly, muscle pain (26%), arthralgia (37%) and malaise (26%) were relatively frequent. These nonhematological toxicities may have diminished the QOL of patients who received protocol therapy.
Two patients experienced Grade 3 or 4 hyponatremia in the present study. The cause was determined to be SIADH induced by cisplatin in one patient. Hyponatremia is often caused by SIADH in cancer patients (14) (15) (16) . Cisplatin stimulates arginine vasopressin secretion, causing SIADH. Cisplatin can also directly damage renal tubules to interfere with sodium Jpn J Clin Oncol 2014;44 (11) reabsorption, which can lead to hyponatremia via salt wasting nephropathy known as 'renal salt wasting syndrome' (17) . The distinction between these two pathological conditions is important because their management differs, and selecting the wrong treatment can exacerbate hyponatremia. Patients with renal salt wasting syndrome have signs of dehydration, and the primary goal of treatment is recovery from dehydration. In contrast, patients with SIADH do not have dehydration, and the main treatment is fluid restriction. The GOG 209 study, which compared TAP therapy with TC therapy in patients with Stages III, IV or recurrent endometrial cancer, revealed that TC therapy is not inferior to TAP therapy in terms of PFS (median PFS of TAP vs. TC, 13.5 vs. 13.3 months; HR, 1.03) and OS (40.3 vs. 36.5 months; HR, 1.05) based on interim analysis results (5). The authors concluded that the toxicity profile favored TC therapy because it caused less sensory neuropathy (sensory neuropathy . Grade 1, 26 vs. 19%; P , 0.01). However, myalgia and arthralgia were markedly frequent in patients undergoing TC therapy. Although gastrointestinal and metabolic toxicities were frequent with TAP therapy, most gastrointestinal toxicities were well-controlled. We believe that TAP therapy will remain an important treatment in the future.
The feasibility of modified TAP therapy is demonstrated in the present study. Prophylactic G-CSF injection may not be necessary in patients without previous RT therapy.
